Gore S, Morris A I, Gilmore I T, Maltby P J, Thornback J R, Billington D
Department of Gastroenterology, Royal Liverpool Hospital, United Kingdom.
J Nucl Med. 1991 Mar;32(3):506-11.
Neogalactosyl albumin (NGA) is a synthetic ligand to the asialoglycoprotein receptor (hepatic binding protein), which has been proposed as a useful receptor binding radiopharmaceutical for the noninvasive assessment of liver function. We have compared the uptake and intracellular processing of iodine-125- (125I) and technetium-99m- (99mTc) NGA following its administration as a 1-min pulse (147 pmol) to the isolated perfused rat liver. Approximately 40% of a pulse of either 125I- or 99mTc-NGA were taken up first pass by the liver. Of the 125I taken up by the liver, 82% was released after 15-20 min at the sinusoidal pole of the hepatocyte, predominantly as small molecular weight metabolites. A further 8% of the 125I-associated radioactivity was secreted as intact NGA into bile by the non-lysosomal (direct) pathway while 6% remained in the liver 1 hr after the pulse. In contrast, of the 99mTc taken up by the liver, only 4% reappeared in the perfusate while 40% was secreted into bile by the lysosomal (indirect) pathway and 55% remained in the liver 1 hr after the pulse. Since labeled metabolites of 99mTc-NGA do not appear in plasma, this permits kinetic modeling with 99mTc-NGA without correction for labeled metabolites. Thus, 99mTc-NGA is an excellent candidate as a receptor-binding radiopharmaceutical.
新半乳糖基白蛋白(NGA)是去唾液酸糖蛋白受体(肝脏结合蛋白)的一种合成配体,已被提议作为一种有用的受体结合放射性药物用于肝功能的无创评估。我们比较了将碘 - 125 - (125I)和锝 - 99m - (99mTc)NGA以1分钟脉冲(147皮摩尔)形式给予离体灌注大鼠肝脏后的摄取和细胞内处理情况。125I - NGA或99mTc - NGA脉冲给药后,约40%在肝脏首次通过时被摄取。肝脏摄取的125I中,82%在15 - 20分钟后在肝细胞的窦状隙极处释放,主要以小分子量代谢产物的形式。另外8%与125I相关的放射性通过非溶酶体(直接)途径作为完整的NGA分泌到胆汁中,而6%在脉冲后1小时仍留在肝脏中。相比之下,肝脏摄取的99mTc中,只有4%重新出现在灌注液中,而40%通过溶酶体(间接)途径分泌到胆汁中,55%在脉冲后1小时仍留在肝脏中。由于99mTc - NGA的标记代谢产物不出现在血浆中,这使得用99mTc - NGA进行动力学建模时无需对标记代谢产物进行校正。因此,99mTc - NGA是作为受体结合放射性药物的极佳候选者。